Structure Therapeutics Reports Highly Positive Phase 2b Data for Oral Obesity Drug Aleniglipron, Advancing to Phase 3
GPCR has more than doubled off its 52-week low of $13.22.
Summary
Structure Therapeutics reported highly positive Phase 2b clinical trial results for its oral obesity drug, aleniglipron, showing significant weight loss and a favorable safety profile, paving the way for Phase 3 development.
Key Events · Product Development and Regulatory · GPCR
-
Positive Phase 2b ACCESS II Results
Aleniglipron achieved a placebo-adjusted mean weight loss of up to 16.3% at 44 weeks, demonstrating high efficacy for an oral GLP-1RA.
-
Improved Tolerability and Safety Profile
A lower 2.5 mg starting dose significantly reduced adverse event-related discontinuations, and the drug maintained a compelling safety profile with no drug-induced liver injury.
-
Advancement to Phase 3
The company plans an End-of-Phase 2 meeting with the FDA in Q2 2026 and anticipates initiating the Phase 3 program in the second half of 2026.
-
Sustained Weight Loss Observed
Interim data from the ACCESS Open-Label Extension study showed continued weight loss up to 16.2% at 56 weeks, with no evidence of a plateau.
Analysis · GPCR · Life Sciences
Structure Therapeutics announced compelling topline results from its Phase 2 ACCESS II trial for aleniglipron, an oral GLP-1 receptor agonist for obesity. The drug demonstrated significant placebo-adjusted mean weight loss of up to 16.3% at 44 weeks, positioning it as a potential best-in-class oral GLP-1RA with efficacy comparable to injectable therapies. The data also highlighted an improved tolerability profile with a lower starting dose and a strong safety record, with no evidence of drug-induced liver injury. These robust results provide a strong foundation for advancing aleniglipron into Phase 3 clinical development, with an FDA meeting scheduled for Q2 2026 and Phase 3 initiation anticipated in 2H 2026. This significantly de-risks the company's lead asset and strengthens its competitive position in the lucrative obesity market.
At the time of this filing, GPCR was trading at $59.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $13.22 to $94.90. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.